Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort

Daniel F. McWilliams¹, Sneha Varughese², Adam Young³, Patrick D. Kiely ⁴ and David A. Walsh¹,²

Abstract

Objective. RA is an important cause of work disability. This study aimed to identify predictive factors for work disability and state benefit claims in a cohort with early RA.

Methods. The Early RA Network (ERAN) inception cohort recruited from 22 centres. At baseline, and during each annual visit, participants (n = 1235) reported employment status and benefits claims and how both were influenced by RA. Survival analysis derived adjusted hazard ratios (aHRs) and 95% CIs to predict associations between baseline factors and time until loss of employment due to RA or a state benefits claim due to RA.

Results. At baseline, 47% of participants were employed and 17% reported claiming benefits due to RA. During follow-up, loss of employment due to RA was reported by 10% (49/475) of the participants and 20% (179/905) began to claim benefits. Independent predictors of earlier work disability were bodily pain (aHR 2.45, 95% CI 1.47, 4.08, P = 0.001) and low vitality (aHR 1.84, 95% CI 1.18, 2.85, P = 0.007). Disability (aHR 1.28, 95% CI 1.02, 1.61, P = 0.033), DAS28 (aHR 1.48, 95% CI 1.05, 2.09, P = 0.026) and extra-articular disease (aHR 1.77, 95% CI 1.17, 2.70, P = 0.007) predicted earlier benefits claims.

Conclusion. Work disability and benefits claims due to RA were predicted by different baseline factors. Pain and low vitality predicted work disability. Baseline disability, extra-articular disease manifestations and disease activity predicted new benefits claims due to RA. Future research on interventions targeting these factors could investigate job retention and financial independence.

Key words: rheumatoid arthritis, employment, social security, work disability.
Methods

Patients and recruitment

The Early RA Network (ERAN) inception cohort study began recruitment in April 2002 and currently recruits from 22 outpatient centres in the UK and Ireland [15]. By the end of February 2012, 1235 patients had been recruited following a clinician diagnosis of RA. Data were collected at baseline, between 3 and 6 months and then annually from baseline. ERAN centres manage patients according to local practice. The ERAN study was approved by the Trent Research Ethics Committee (reference 01/4/047) and all participants gave signed, informed consent in accordance with the Declaration of Helsinki.

Data collection

Data collected at baseline and until the most recent follow-up was used in this study. A clinical interview and examination was performed at each visit and participants continued to receive standard care from their rheumatologists throughout the study. At baseline, clinicians recorded standard demographics (age, sex, height and weight), known extra-articular disease manifestations [16] and co-morbidities [17]. The presence of erosions at baseline was identified from radiographs of the hands and feet. Patients completed the 36-item Short Form (SF-36) Health Survey for patient-based assessment of quality of life [18, 19] and the HAQ [20]. At baseline, and during each annual study visit, patients were asked to report employment, job loss (including whether they believed the job loss was due to RA), retirement and whether they were claiming benefits due to RA (including, but not restricted to, disability benefits claims). ESR and RF were obtained from clinical records. Negative or weakly positive results for RF according to local reference ranges were classified as seronegative. Using data from the ERAN database, the 28-joint DAS (DAS28)–ESR score was derived and the patient-derived DAS28 (DAS28-P) was calculated for those with active disease [21]. The DAS28-P is calculated as the proportion of the DAS28 score that is derived from the patient-reported components, namely tender joint counts and patient global health assessments. The DAS28-P is proposed to be associated with non-inflammatory pain mechanisms and central sensitization. The DAS28-P may represent a component of the pain phenotype related to fibromyalgianess that is distinct from current pain severity [21]. After data collection it was determined whether four or more of the 1987 ACR RA diagnostic criteria were met [22]. The type of employment at baseline was recorded in the text at the study visit and coded using the International Standard Classification of Occupations 2008 (ISCO-08) and classified as heavy work or non-heavy work (semi-manual or less) according to a previously published methodology [23]. Current postcodes were used to estimate the socioeconomic deprivation derived from the UK government’s 2007 rankings [Index of Multiple Deprivation (IMD) 2007 rankings].

Work disability due to RA

At baseline, participants reported whether they were working or not. At baseline, participants of working age were compared with those that reported active employment. Work disability was defined as the loss of employment due to RA, and this was specifically reported by each participant. For the analysis of job loss due to RA during follow-up, only participants who were working at baseline were included. At each visit participants indicated if they were still working, stopped temporarily, were not currently employed or retired. Each participant also reported whether the loss of employment was due to RA or not. The time until the first job loss due to RA (including concurrent job loss due to RA and first retirement) was derived from these data. Temporary sick leave was not included as a loss of employment, although it was recorded during data collection. After 2 years of being classified as temporary sick leave, we included these people as losing employment. No additional checks were made by investigators into the claims that RA was the cause of loss of employment or whether there were multiple contributing factors.

Benefit claims due to RA

At baseline, participants reported whether they were claiming benefits due to RA or not. For the analysis of time until benefits claims, only those participants who were not claiming at baseline were included. At each visit participants indicated if they were claiming benefits due to RA, and the time until the first benefits claim was derived from these data. The specific benefits being claimed due to RA were not recorded, and each participant self-reported the data.
Statistical analysis

Univariate data analyses were performed using Mann–Whitney U-tests, and log-rank or χ² tests were used for categorical data, to compare baseline factors between participants with different work and benefit statuses. Correlations of categorical data were performed using Spearman’s coefficient. DAS28 scores were classified into European League Against Rheumatism (EULAR) disease activity groups (0–3.19, 3.2–5.19, ≥5.2) [24] and EULAR response groups comparing baseline and 1-year follow-up [16], and BMI was classified into World Health Organization (WHO) groups (<25, 25–29.9, ≥30) [25]. For each SF-36 questionnaire subscale (Bodily Pain, Mental Health, Vitality and Physical Function), the raw scores between 0 and 100 were used and not normed for age and gender [19] because these were included as covariates in the analyses. The eligible populations for the analyses of loss of employment due to RA and RA benefit claims were derived and continuous variables were split into quartiles of increasing severity or magnitude within each group. Up until Year 2, follow-up times were calculated as the number of days until an event of interest or right censorship. This was performed to produce accurate estimates of the influence of short follow-up times. Beyond 2 years, the year of each annual visit was used. Survival analysis was performed and Cox regression was used to calculate hazard ratios (HRs), adjusted HRs (aHRs) and 95% CIs to estimate the annual probability of early loss to follow-up, the inclusion of people from Ireland and different extra-articular manifestations on our main analyses. From baseline to 1 year, EULAR response categories [26] were calculated from people with DAS28 >3.2, the minimum disease activity required to obtain a good assessment. SPSS version 16 (IBM, Armonk, NY, USA) was used to perform the analyses and P < 0.05 was statistically significant.

Results

At baseline, participants (n = 1235, 68% female) had a median (interquartile range (IQR)) age of 58 (47–98) years. Forty-seven per cent reported that they were employed at baseline. Also 17% of patients (210/1206) reported claiming benefits due to RA (Table 1). The initial DMARD treatments were MTX monotherapy in 46% (522/1134), SSZ monotherapy in 31% (351/1134) and medication in ERAN has been described in more detail elsewhere [27].

Univariate analyses of baseline characteristics (Table 1) indicated that non-workers of working age were older and exhibited more co-morbidities and higher disease activity, pain and disability as well as lower physical function, vitality and mental health than workers. Non-workers were also more likely to have a history of smoking, but not to be current smokers (workers 29% vs non-workers 32%, P = 0.484). Heterogeneity was seen between benefit claimants and non-claimants, with regard to age, sex, symptoms and levels of disability. Significant differences between subgroups are highlighted in bold.

Table 1 Demographics of the ERAN cohort and subgroups

| Baseline variable | Whole cohort | Working | Not working | Benefits | No benefits |
|------------------|--------------|---------|-------------|-----------|-------------|
| n                | 1235         | 567     | 227         | 210       | 974         |
| Age, years       | 58 (47–98)   | 50 (42–57)** | 55 (45–59) | 60 (50–69)* | 57 (47–67) |
| BMI, kg/m²       | 26.8 (23.9–30.4) | 26.9 (24.0–30.3) | 26.8 (24.0–31.8) | 26.8 (24.2–31.4) | 26.8 (23.8–30.2) |
| Female gender, % | 68           | 66      | 70          | 69        | 68          |
| Smoking history, % | 61          | 58**    | 70          | 71**      | 59          |
| ACR criteria, %  | 53           | 49      | 55          | 56        | 53          |
| Seropositive, %  | 61           | 63      | 61          | 54*       | 62          |
| Extra-articular disease, % | 15        | 14      | 18          | 17        | 15          |
| Erosions, %      | 29           | 27      | 29          | 35*       | 28          |
| Co-morbidity, %  | 44           | 39**    | 49          | 52**      | 42          |
| DAS28            | 4.8 (3.6–5.8) | 4.4 (3.3–5.5)** | 5.2 (4.0–6.3) | 5.17 (4.27–6.28)** | 4.68 (3.52–5.75) |
| Symptom duration, months | 6 (3–12) | 6 (4–13) | 6 (4–13) | 7 (3–13) | 6 (3–12) |
| HAQ              | 1.0 (1.0–1.63) | 1.0 (0.9–1.4) | 1.0 (0.9–1.4) | 1.0 (0.9–1.4) | 1.0 (0.9–1.4) |
| SF-36 Bodily Pain | 41 (22–62) | 41 (31–62)** | 41 (31–62)** | 41 (31–62) | 41 (31–62) |
| SF-36 Physical Function | 50 (30–75) | 60 (40–80)** | 35 (15–66) | 30 (11–56)** | 50 (32–75) |
| SF-36 Vitality   | 44 (25–56)   | 44 (25–56)** | 38 (19–50)** | 44 (25–56) | 44 (25–56) |
| SF-36 Mental Health | 68 (52–80) | 70 (55–80)** | 60 (45–80) | 60 (48–76)** | 70 (55–84) |

The demographics of the ERAN cohort are shown with univariate comparisons between each of the subgroups. Values are the percentage, median (interquartile range) or the number in each subgroup. ACR: 1987 American College of Rheumatology criteria for RA. Univariate Mann–Whitney U or χ² tests **P < 0.01 and *P < 0.05, comparing working with not-working participants (of working age) or those claiming benefits compared with those not on benefits (all ages). Significant differences between subgroups are highlighted in bold.
radiographic erosions, co-morbidities, smoking, disease activity, disability, mental health, pain and vitality.

The median (IQR) follow-up period was 3 (1–4) years. A Kaplan–Meier plot of incident work disability is presented in Fig. 1A. Ten per cent (49/475) of participants who had been employed at baseline reported losing their employment due to RA before their most recent follow-up, and of these, 53% (26/49) reported losing their job due to RA within the first 2 years after baseline assessment. Eighty-four per cent (41/49) of these participants retired when they lost their job. Of these 49 people, only 5 reported a later return to work during the time captured during follow-up.

A Kaplan–Meier plot of incident benefit claims due to RA is presented in Fig. 1B. Twenty per cent (179/905) of participants who were not claiming benefits at baseline began to claim benefits due to RA during follow-up, and 28% (50/179) began within 2 years of baseline. Twenty-nine participants reported both job loss due to RA and new benefit claims. Fourteen participants reported job loss due to RA without benefit claims, and six people reported job loss but had missing benefits data. The major DMARDs initiated first (monotherapies of HCQ, SSZ, MTX or combination therapies including MTX) were not associated with times until work disability ($\chi^2 = 3.3$, df = 3, $P = 0.354$) or benefits claims due to RA ($\chi^2 = 1.1$, df = 3, $P = 0.775$).

Table 2 displays survival analysis using Cox regression analyses for baseline factors associated with earlier time until work disability (job loss due to RA). Unadjusted HRs showed that increased disease activity, disability (HAQ), bodily pain, smoking, low vitality and poorer mental health were associated with earlier work disability. Additionally, univariate log-rank tests stratified by the ERAN study centre did not find significant heterogeneity between sites ($\chi^2 = 11.1$, df = 15, $P = 0.748$). After adjustment, independent predictors for earlier work disability were worse bodily pain and low vitality. Sensitivity analyses that excluded people with a short ($\leq 1$ year) follow-up or that excluded people from Ireland ($n = 28$) did not remove the statistical significance of bodily pain or vitality (data not shown).

The survival analysis presented in Table 3 shows the associations between baseline factors and earlier benefit claims due to RA. HAQ disability, disease activity, extra-articular disease, lower vitality, worse bodily pain, poorer mental health and meeting 1987 ACR criteria were associated with earlier benefit claims. Additionally, univariate log-rank tests stratified by the ERAN study centre did not find significant heterogeneity between sites ($\chi^2 = 22$, df = 15, $P = 0.102$). After adjustments, independent predictors of earlier benefits claims were DAS28, HAQ disability and extra-articular disease. The most common extra-articular disease manifestations [nodules ($n = 65$), Sjögren’s syndrome ($n = 17$) and Raynaud’s disease ($n = 36$)] were each analysed separately. Reported nodules at baseline were significantly associated with the first RA benefits claim before (HR 1.74, 95% CI 1.12, 2.73, $P = 0.015$) and after adjustment for the same confounders (aHR 1.92, 95% CI 1.13, 3.26, $P = 0.016$). Sjögren’s syndrome and Raynaud’s disease did not show significant associations with benefits claims due to RA at either level (data not shown). None of these three extra-articular manifestations were significantly associated with RA job loss (data not shown). Additionally, excluding people from Ireland did not remove the statistical significance of the DAS28, HAQ and extra-articular manifestations (data not shown).

Patients with a baseline DAS28 $>3.2$ (the lowest DAS28 value where a good EULAR response was possible) were...
## Table 3

**Predictors for new benefits claims due to RA**

| Baseline variable   | Unadjusted |          |          | Adjusted |          |          |
|---------------------|------------|----------|----------|----------|----------|----------|
|                     | HR (95% CI) | P-value  |          | aHR (95% CI) |          | P-value  |
| Age Quartiles       | 1.30 (0.98, 1.71) | 0.067    | 1.25 (0.88, 1.76) | 0.209    |
| Gender Female       | 0.86 (0.53, 1.71) | 0.860    | 1.21 (0.53, 2.75) | 0.647    |
| BMI WHO groups      | 1.31 (0.90, 1.90) | 0.161    | Not used |          |          |
| High deprivation    | Top quartile | 1.21 (0.50, 2.89) | 0.673 | Not used |          |          |
| Manual work Y/N     | 1.83 (1.01, 3.31) | <0.001   | Not used |          |          |
| Heavy work Y/N      | 1.97 (1.07, 3.62) | <0.001   | 1.27 (0.57, 2.84) | 0.559    |
| Ever smoked? Y/N    | 2.36 (1.25, 4.46) | <0.001   | 1.91 (0.89, 5.76) | 0.096    |
| Current smoker Y/N  | 1.42 (0.77, 2.61) | 0.264    | Not used |          |          |
| DAS28 EULAR groups  | 1.82 (1.17, 2.85) | <0.001   | 0.96 (0.53, 1.74) | 0.901    |
| 1987 ACR criteria Y/N | 1.30 (0.73, 2.31) | 0.373    | Not used |          |          |
| Seropositive Y/N    | 0.61 (0.33, 1.12) | 0.113    | Not used |          |          |
| Symptom duration    | Quartiles | 0.81 (0.61, 1.08) | 0.147 | Not used |          |          |
| Disability (HAQ)    | 1.60 (0.80, 3.23) | 0.187    | Not used |          |          |
| SF-36 Bodily Pain   | Quartiles | 1.69 (1.25, 2.28) | <0.001 | 0.93 (0.60, 1.44) | 0.744    |
| SF-36 Vitality      | Quartiles | 2.63 (1.76, 3.92) | <0.001 | 2.45 (1.47, 4.08) | 0.001    |
| SF-36 Mental Health | Quartiles | 1.84 (1.34, 2.53) | <0.001 | 1.84 (1.18, 2.85) | 0.007    |
| Co-morbidities Y/N  | 1.24 (0.69, 2.23) | 0.464    | Not used |          |          |
| DAS28-P             | Quartiles | 1.03 (0.77, 1.39) | 0.842 | Not used |          |          |

### Cox regression analyses

Cox regression analyses for baseline variables associated with shorter times until first RA benefits claims. Unadjusted analyses were performed for each variable. Important demographics, age, gender, DAS28 and others that were close to significance were selected for the multivariable cox regression. HRs and aHRs are presented with 95% CIs and P-values. 

*Significant results.

---

## Table 2

**Predictors for loss of employment due to RA**

| Baseline variable   | Unadjusted |          |          | Adjusted |          |          |
|---------------------|------------|----------|----------|----------|----------|----------|
|                     | HR (95% CI) | P-value  |          | aHR (95% CI) |          | P-value  |
| Age Quartiles       | 1.30 (0.98, 1.71) | 0.067    | 1.25 (0.88, 1.76) | 0.209    |
| Gender Female       | 0.86 (0.53, 1.71) | 0.860    | 1.21 (0.53, 2.75) | 0.647    |
| BMI WHO groups      | 1.31 (0.90, 1.90) | 0.161    | Not used |          |          |
| High deprivation    | Top quartile | 1.21 (0.50, 2.89) | 0.673 | Not used |          |          |
| Manual work Y/N     | 1.83 (1.01, 3.31) | <0.001   | Not used |          |          |
| Heavy work Y/N      | 1.97 (1.07, 3.62) | <0.001   | 1.27 (0.57, 2.84) | 0.559    |
| Ever smoked? Y/N    | 2.36 (1.25, 4.46) | <0.001   | 1.91 (0.89, 5.76) | 0.096    |
| Current smoker Y/N  | 1.42 (0.77, 2.61) | 0.264    | Not used |          |          |
| DAS28 EULAR groups  | 1.82 (1.17, 2.85) | <0.001   | 0.96 (0.53, 1.74) | 0.901    |
| 1987 ACR criteria Y/N | 1.30 (0.73, 2.31) | 0.373    | Not used |          |          |
| Seropositive Y/N    | 0.61 (0.33, 1.12) | 0.113    | Not used |          |          |
| Symptom duration    | Quartiles | 0.81 (0.61, 1.08) | 0.147 | Not used |          |          |
| Disability (HAQ)    | 1.60 (0.80, 3.23) | 0.187    | Not used |          |          |
| SF-36 Bodily Pain   | Quartiles | 1.69 (1.25, 2.28) | <0.001 | 0.93 (0.60, 1.44) | 0.744    |
| SF-36 Vitality      | Quartiles | 2.63 (1.76, 3.92) | <0.001 | 2.45 (1.47, 4.08) | 0.001    |
| SF-36 Mental Health | Quartiles | 1.84 (1.34, 2.53) | <0.001 | 1.84 (1.18, 2.85) | 0.007    |
| Co-morbidities Y/N  | 1.24 (0.69, 2.23) | 0.464    | Not used |          |          |
| DAS28-P             | Quartiles | 1.03 (0.77, 1.39) | 0.842 | Not used |          |          |

### Cox regression analyses

Cox regression analyses for baseline variables associated with shorter times until loss of employment due to RA. Unadjusted analyses were performed for each variable. Important demographics, age, gender, DAS28 and others that were close to significance were selected for the multivariable cox regression. HRs and aHRs are presented with 95% CIs and P-values. 

*Significant results.

---

**ACR:** 1987 American College of Rheumatology criteria for RA. 

*Significant results.*
categorized into good, moderate and no response according to EULAR response criteria at 1 year [26]. New work disability was found in 9% (7/74) of good, 18% (9/51) of moderate and 13% (10/76) of no response participants at 1 year ($\chi^2 = 1.8, P = 0.406$). The trend for EULAR response to predict work disability was not significant ($r = 0.05, P = 0.510$). New benefits claims due to RA were found in 17% (20/121) of good, 27% (33/121) of moderate and 31% (49/157) of no response participants at 1 year ($\chi^2 = 8.1, P = 0.018$). Better EULAR response was associated with a lower probability of new benefits claims ($r = 0.14, P = 0.007$).

**Discussion**

We found that baseline factors that most strongly predicted work disability due to RA were bodily pain and vitality. These are symptoms that may respond poorly to traditional medical treatments that focus on disease activity, and additional symptom-focused treatments may have the potential to facilitate job retention. We have previously shown that reported pain remains high during follow-up of people with early RA in the ERAN cohort [28], and factors such as central sensitization in addition to inflammatory disease activity may contribute to poor pain outcomes [21]. Other studies have also demonstrated an increased risk of work disability due to increased bodily pain [29] and that the SF-36 Bodily Pain subscale predicted continuous 1-year sick leave in people with musculoskeletal pain [30]. Low vitality may be related to greater fatigue and less desire to continue working [31], and pain and fatigue contribute substantially to physical disability in RA [32], providing plausible explanations for associations with work disability. Often work disability can occur within the early years from diagnosis [33] and people who lose their jobs are unlikely to return to work [34]. We found that 53% (26/49) of people that reported work disability due to RA did so within 2 years. Greater attention to the alleviation of pain and fatigue in the management of early RA may facilitate job retention.

An association between the SF-36 Mental Health subscale and work disability was demonstrated in one study of RA [35], but we and another study [36] found that any such association was not independent of other covariates. Older age [37], HAQ disability [4, 23, 34] and physically demanding employment [8, 23, 34] have each been reported to be associated with work disability in previous studies [38]. Greater self-reported disability may be expected to make continuing employment more difficult, either because of physically demanding jobs, difficult commutes [5, 6, 39] or lack of support [5, 6]. However, in the ERAN cohort, adjustments for other confounders removed the statistical significance from these factors in our survival analysis, implying a lesser risk from them than from pain and low vitality. Geographical influences may account for differences in work disability across studies, as rates can vary between countries [40], and most of the literature regarding work disability in RA comes from countries other than the UK. It is worth noting that loss of employment due to RA does not always correspond with a new benefits claim. Some benefits may be claimed by those in work (due to disability or low-income employment); also some people leaving work due to RA might not consider their subsequent benefits claims as being due to RA. Benefits for supplementing income might not be reported to ERAN investigators as due to RA, or may not be claimed by all eligible participants.

Baseline factors that most strongly predicted benefits claims due to RA were disease activity, greater disability and the presence of extra-articular disease. The association of benefit claims with baseline extra-articular disease was not explained by greater disability, nor by higher disease activity scores, as it persisted despite adjustment for other factors. Further research is required to determine whether extra-articular disease influences the likelihood that people with RA will apply for benefits or whether it has an influence on the likelihood that benefits will be awarded. When rheumatoid nodules, Sjögren’s syndrome and Raynaud’s disease were modelled separately, only nodules continued to show a significant association with benefits claims due to RA. However, nodules were the most frequently noted extra-articular features, and our study may not have had sufficient power to detect associations with less common manifestations. Other studies have reported associations between functional capacity and disability payments [4, 14, 41]. The association with baseline HAQ may be expected, as benefits are dependent on the extent of reported disability.

Our data provide some evidence that achieving better EULAR response improves the likelihood that people with RA will not subsequently claim benefits. Interpretation of the lack of observed statistical association between EULAR response and job loss is limited by the small number of participants that could be included in the analysis. Previous studies have demonstrated that treatments that improve inflammatory disease activity in RA can reduce time away from work [42], and further research is necessary to determine the extent to which improved disease-modifying strategies could further reduce work disability compared with the contemporary practice represented by the ERAN cohort.

We present evidence that different baseline factors predict job loss and benefit claims. In particular, both in unadjusted and adjusted analyses, bodily pain predicted loss of employment more strongly than it predicted new benefits claims. Loss of employment and new benefits claims represent distinct aspects of work disability and different strategies may need to be adopted to reduce their impact. Attention to the pain experienced by people with early RA may have a particular impact on job retention.

Data on education level are not available for the ERAN cohort, but may contribute to success in benefits claims. For example, the ability to complete forms or to appeal adverse benefits decisions may influence the success of benefits claims. Education level may also affect job loss and benefits claims by determining employment type and flexibility or contributing to social deprivation. However, we found that high socioeconomic deprivation and
manual work were not specifically associated with loss of employment or new benefits claims due to RA. ERAN recruited from diverse regions of the UK and also from Ireland. However, we did not find evidence that regional variations influenced our findings. No significant heterogeneity was detected between ERAN centres at the univariate level for time until job loss due to RA and benefits claims due to RA, and exclusion of Ireland in our sensitivity analyses did not affect our results. One strength of the ERAN study was that participants were specifically asked to assign a reason for loss of employment, which allowed us to determine work disability due to RA rather than job loss. The predictors of work disability and benefits claims in this study are all readily measured in ordinary clinical settings and could be used routinely. Limitations of this study include the relatively short follow-up and that self-reported information was not verified independently. The UK benefits system requires access to information contained within medical records to validate the process of benefit award, and responses to self-report questionnaires may be influenced by a desire to facilitate potential claims. The data do not identify the type of benefit claimed and our research relied on participants’ self-reported relationship between benefits claims and RA. Further research is required to fully explore the possibly complex interactions between RA and other factors that may mediate job loss and benefits claims and would ideally include both qualitative and quantitative methodologies and data from a variety of sources. A proportion of participants may not have applied for social security benefits because of financial security, lack of information or because of negative perceptions of benefit claims. Factors that influence benefit claims in the UK (and Ireland) may not be generalizable to other populations. A greater proportion of people with RA claim benefits in European vs North American studies, possibly due to greater accessibility to welfare facilities within Europe and different insurance systems [40, 43, 44].

In conclusion, work disability is a major issue for people with early RA, as manifested by high job loss and benefits claims. Work disability and benefits claims are common in people with newly diagnosed RA. Different baseline factors predict job loss or benefits claims, with pain being a major predictor of subsequent job loss. Greater attention to work disability during the initial assessment of people with RA could lead to interventions that reduce its impact in later disease. Attention to factors such as pain, vitality and reported disability, as well as inflammatory disease activity, has the potential to reduce subsequent work disability in people presenting with early RA.

Acknowledgements

Project management and source data verification: Ms W. Garwood and Ms M Hunt; data handling and entry: Ms C. Mayes, Ms M Hunt. ERAN Coordinating Centre, Rheumatology Research & Audit Office, St Albans City Hospital, Herts, UK. ERAN recruiting centres for this study: Dr M. Webley, Dr S. Edmonds, J. Hall (Aylesbury); Dr P. Prouse, S. Andrews (Basingstoke); Dr K. Adams, R Hunter (Bolton); Dr P. Creamer, J. Taylor, G. Bath, W. Wilmott (Bristol); Dr C. Dunne, L. Hawley (Christchurch); Dr J. Griffin, P. Goodman (Enfield); Dr A. Couiston, S. Morris (Haverfordwest); Dr R. Williams, K. Blunn, J. McDowell, H. Robinson (Hereford); Dr M. Bukhari, Dr J. Halsey, B. Evans (Lancaster); Dr P. D. Kiely, F. Leone (St George’s, London); Dr D.A. Walsh, Dr N. Carter, D. Wilson (Mansfield); Dr J. David, M. Cox (Oxford); Dr A. Young, A. Seymour, M. Hunt (St Albans); Dr A. Hassell, M. Kirwan, E. Barcroft (Stoke-on-Trent); Dr J. Devlin, C. Duffey (Waterford, Ireland); Dr S. Clarke, Dr S. Green, B. Williams, D. Simmons (Weston-super-Mare); Dr T. Palferman, Dr S. Knights, C. Buckley, R. Rowland-Axe (Yeovil).

Funding: This study was funded by Pfizer (grant number WS953552). The study sponsors did not have any input into the study design, analysis, manuscript preparation or decision to publish.

Disclosure statement: D.F.M. and D.A.W. are supported by grants from Pfizer. All other authors have declared no conflicts of interest.

References

1 Symmons DP, Barrett EM, Bankhead CR et al. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735–9.
2 Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoconomics 2004;22(Suppl. 1): 1–12.
3 Puolakka K, Kautiainen H, Mottonen T et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005;64:130–3.
4 Barrett EM, Scott DG, Wiles NJ et al. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology 2000;39:1403–9.
5 NRAS. National Rheumatoid Arthritis Society Survey 2007: I Want to Work2007, http://www.nras.org.uk/includes/documents/cm_docs/2010/f/final_final_work_survey.pdf (28 October 2013, date last accessed).
6 NRAS. RA and Work: Employment and Rheumatoid Arthritis in Scotland. A National Picture 2010, http://www.nras.org.uk/includes/documents/cm_docs/2010/j/j4660_scottish_survey_doc_revised.pdf (28 October 2013, date last accessed).
7 Merkesdal S, Ruof J, Huelselmann JL et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient

Rheumatology key messages

- More pain and less vitality at baseline predicted job loss due to RA.
- Disability, higher DAS28 and extra-articular manifestations predicted new state benefits claims due to RA.
questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005;53:234–40.
8 Verstappen SM, Bijlisma JW, Verkleij H et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488–97.
9 Gilworth G, Chamberlain MA, Harvey A et al. Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum 2003;49:349–54.
10 Berthoud R. Measuring the impact of disability benefits: a feasibility study. London: HMSO, 2009.
11 NRAS. Benefits and Rheumatoid Arthritis—A Simple Guide to the Main Benefits that could be Available to People with RA, 2012. http://www.nras.org.uk/includes/documents/cm_docs/2010/jj4203_revised_purple_benefits_booklet_final.pdf (28 October 2013, date last accessed).
12 DirectGov. Benefits and financial support. 2012. http://www.direct.gov.uk/en/MoneyTaxAndBenefits/BenefitsTaxCreditsAndOtherSupport/index.htm (28 October 2013, date last accessed).
13 Department for Work and Pensions. Benefits. 2013. http://www.gov.uk/browse/benefits (28 October 2013, date last accessed).
14 de Croon EM, Sluijer JK, Nijsen TF et al. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2004;63:1362–7.
15 Garwood W. The Early Rheumatoid Arthritis Network (ERAN), Musculoskeletal Care 2004;2:240–4.
16 Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:907–27.
17 Young A, Koduri G, Batley M et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007;46:350–7.
18 Ruta DA, Hurst NP, Kind P et al. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol 1998;37:425–36.
19 Ware JE, Snow KK, Kosinski M. SF-36 health survey: manual and interpretation guide. 2nd edn. Lincoln: QualityMetric, 2000.
20 Fries JF, Spitz P, Kraines RG et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
21 McWilliams DF, Zhang W, Mansell JS et al. Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. Arthritis Care Res 2012;64:1505–13.
22 Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–24.
23 Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61:335–40.
24 van Riel PL, Schumacher HR Jr. How does one assess early rheumatoid arthritis in daily clinical practice? Best Pract Res Clin Rheumatol 2001;15:67–76.
25 World Health Organisation. Global database on body mass index. . http://apps.who.int/bmi/index.jsp?introPage=intro_3.html (28 October 2013, date last accessed).
26 van Gestel AM, Prevoo ML, van ’t Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34–40.
27 Kiley P, Williams R, Walsh D et al. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology 2009;48:57–60.
28 Walsh DA, McWilliams DF. Pain in rheumatoid arthritis. Curr Pain Headache Rep 2012;16:509–17.
29 Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108–17.
30 Atrosi I, Andersson IH, Gummesson C et al. Primary care patients with musculoskeletal pain. Value of health-status and sense-of-coherence measures in predicting long-term work disability. Scand J Rheumatol 2002;31:239–44.
31 Reisine S, McQuillan J, Fife J. Predictors of work disability in rheumatoid arthritis patients. A five-year followup. Arthritis Rheum 1995;38:1630–7.
32 Toussirot E. Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review. Inflamm Allergy Drug Targets 2010;9:51–9.
33 Nikipherou E, Guh D, Bansback N et al. Work disability rates in RA. Results from an inception cohort with 24 years follow-up. Rheumatology 2012;51:385–92.
34 Verstappen SM, Boonen A, Bijlisma JW et al. Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions. Rheumatology 2005;44:202–6.
35 Wallenius M, Skomsvoll JF, Koldingsnes W et al. Comparison of work disability and health-related quality of life between males and females with rheumatoid arthritis below the age of 45 years. Scand J Rheumatol 2009;38: 178–83.
36 Odengard S, Finset A, Kvien TK et al. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol 2005;34:411–7.
37 Allaire S, Wolfe F, Niu J et al. Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort. Arthritis Rheum 2009;61:321–8.
38 Burton W, Morrison A, Maclean R et al. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 2006;56:18–27.
39 Allaire SH, Anderson JJ, Meenan RF. Reducing work disability associated with rheumatoid arthritis: identification of additional risk factors and persons likely to benefit from intervention. Arthritis Care Res 1996;9:349–57.
40 Chung CP, Sokka T, Arbogast PG et al. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006;65:1653–7.
41 Sokka T, Kautiainen H, Pincus T et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12:R42.

42 Augustsson J, Neovius M, Cullinane-Carli C et al. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 2010;69:126–31.

43 Albers JM, Kuper HH, van Riel PL et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology 1999;38:423–30.

44 Doeglas D, Suurmeijer T, Krol B et al. Work disability in early rheumatoid arthritis. Ann Rheum Dis 1995;54:455–60.